Table 2.
Bivariate analysis of risk factors for 1-year mortalitya
| Variable | Alive (n = 39) | Dead (n = 22) | OR (95% CI) | p |
|---|---|---|---|---|
| Demographic data | ||||
| Age >65 years | 16 (40%) | 11 (50%) | 1.5 (0.5–4.9) | 0.593 |
| Male sex | 31 (78%) | 15 (68%) | 0.62 (0.2–2.4) | 0.546 |
| Prosthetic valve IE | 11 (29%) | 3 (14%) | 0.41 (0.1–1.9) | 0.338 |
| Diabetes | 8 (20%) | 4 (18%) | 0.89 (0.2–3.9) | 1.000 |
| Community acquisition | 26 (65%) | 14 (64%) | 1.76 (0.0–141.9) | 0.889 |
| North America | 8 (20%) | 6 (27%) | 1.77 (0.1–143.1) | 0.444 |
| Clinical features | ||||
| Paravalvular complications | 8 (20%) | 11 (50%) | 4.0 (1.1–14.6) | 0.021 |
| Stroke | 6 (15%) | 10 (46%) | 4.72 (1.2–19.1) | 0.015 |
| Heart failure | 10 (46%) | 10 (46%) | 1.73 (0.5–5.7) | 0.411 |
| Persistent bacteraemia | 5 (13%) | 3 (14%) | 1.11 (0.2–6.4) | 1.000 |
| Surgery | 14 (35%) | 9 (41%) | 1.29 (0.4–4.2) | 0.785 |
| Microbiologic features | ||||
| Vancomycin MIC ≥1.5 mg/L | 24 (60%) | 10 (45%) | 0.56 (0.2–1.8) | 0.298 |
| CC30 | 7 (18%) | 6 (27%) | 1.77 (0.4–7.3) | 0.516 |
| CC8 | 1 (3%) | 3 (14%) | 6.16 (0.4–331.3) | 0.546 |
| CC15 | 6 (15%) | 0 | 0.0 (0–1.1) | 0.081 |
| agrI | 15 (38%) | 7 (32%) | 0.78 (0.2–2.6) | 0.784 |
| agrII | 13 (33%) | 6 (27%) | 0.78 (0.2–2.7) | 0.777 |
| agrIII | 11 (28%) | 9 (41%) | 1.83 (0.5–6.2) | 0.394 |
| see | 8 (20%) | 10 (46%) | 3.33 (0.9–12.2) | 0.044 |
| sei | 33 (83%) | 22 (100%) | 2.94 (1.1–13.7) | 0.044 |
| chp | 39 (98) | 16 (73%) | 0.07 (0.0–0.7) | 0.006 |
| eta | 8 (20%) | 6 (27%) | 1.5 (0.4–5.9) | 0.539 |
| pvl | 4 (10%) | 5 (23%) | 2.65 (0.5–14.9) | 0.259 |
CC, clonal complex; CI, confidence interval; IE, infective endocarditis; MIC, minimum inhibitory concentration; OR, odds ratio.
a
Analysis for in-hospital mortality using the same variables did not differ from that of 1-year mortality (data not shown).